Navigation Links
Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
Date:6/10/2008

Collaboration to Apply Chemetics(R) Technology to Lexicon Targets

COPENHAGEN, June 10 /PRNewswire/ -- Nuevolution A/S today announced a strategic alliance with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) aimed at the discovery of novel small molecule lead compounds for highly validated drug targets.

Under the terms of the alliance, Nuevolution's proprietary Chemetics(R) drug discovery technology will be applied to identify novel small molecule lead compounds against a range of drug targets proposed by Lexicon. Nuevolution will receive an upfront payment and will be eligible for milestone payments and royalties on compounds identified using its technology as candidate molecules progress through preclinical and clinical development and onto the market. At a future point in time, Nuevolution will have the option to expand its involvement in certain programs under a cost and profit sharing arrangement.

The collaboration will harness the power of Nuevolution's Chemetics(R) platform technology which enables both hit identification and hit-to-lead optimization by exploration of ultra large chemistry space through the screening of multiple fragment-based small molecule libraries of more than 100 million compounds per library.

The validated targets have been identified through Lexicon's Genome5000TM program where the company explored the physiological and behavioral function for nearly 5,000 human genes by studying the corresponding mouse genes in knockout animals. This endeavor led to the identification of more than 100 highly validated drug targets that Lexicon is using to build a unique and growing clinical pipeline.

"Our proprietary Chemetics(R) platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale," said Alex Gouliaev, CEO of Nuevolution A/S. "We believe this generates high quality hits and leads far more rapidly and reliably than current ultra high throughput methods. Combining our platform with Lexicon's highly validated target portfolio represents an exceptional drug discovery opportunity and we very much look forward to bringing together Lexicon's expertise in biology and ours in chemistry, creating a synergistic biotech alliance."

"This important alliance is designed to accelerate Lexicon's ability to move from novel knockout validated targets to drug candidates as we continue to build our pipeline of innovative products," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer of Lexicon.

About Nuevolution

Nuevolution is a leading drug discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Venture and Novo A/S.

For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Co., Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

For further information please contact:

Nuevolution A/S

Danish media International media

Alex Haahr Gouliaev, CEO Chris Gardner/Mark Swallow

Phone: +45-7020-0987 Phone: +44(0)207-282-2995/+44(0)207-282-2948

ahg@nuevolution.com chris.gardner@citigatedr.co.uk

Lexicon Pharmaceuticals, Inc.

Stephen Tragash, Executive Director, Corporate Affairs

Phone: +1-281-863-3787

stragash@lexpharma.com


'/>"/>
SOURCE Nuevolution A/S
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. onTargetjobs Announces Appointment of Michael Tansey as New CEO
2. Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test
3. QLT announces positive Health Canada decision on Aczone(R)
4. ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01%
5. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
6. Biopure Announces MHRA Meeting Update
7. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
8. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
9. American Oriental Bioengineering Announces that it Withdraws Convertible Preferred Stock Offering
10. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
11. Synthetech Announces Fiscal 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... , ... Lajollacooks4u, San Diego’s premier team building events and cooking events company, ... offerings and company expansion. , This is largely due to its team ... 30 people. Ever since, Lajollacooks4u has seen significant demand for its services from organizations ...
(Date:12/8/2016)... 2016 AskLinkerReports.com has published a report ... Amyloglucosidase Industry 2016 Market Research Report. From a basic outline ... overview are all covered in the report. This report projects ... analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... Iowa , Dec. 8, 2016 Eurofins announces the ... Food and President of Eurofins Scientific Inc. (ESI). ... with his proven professional and entrepreneurial experience in leading international business ... the US food testing market to uphold Eurofins, status as the ... ...
(Date:12/8/2016)... 8, 2016 Oxford ... erweitert seine Palette an anpassbaren SureSeq™ NGS-Panels mit ... Panels, das ein schnelles und kostengünstiges Studium der ... bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, ... einzigen kleinen Panel und ermöglicht eine individuelle Anpassung ...
Breaking Biology Technology:
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):